Prescribing Guides
Atorvastatin Prescribing Guide for Indian Clinical Practice
Evidence-based atorvastatin prescribing for Indian clinicians with dosing, statin intensity, monitoring, drug interactions and NEET PG pharmacology.
MedNext Editorial Team | 2026-08-01 | 8 min read
Atorvastatin Prescribing Guide for Indian Clinical Practice
Evidence-based atorvastatin prescribing for Indian clinicians with dosing, statin intensity, monitoring, drug interactions and NEET PG pharmacology.
Atorvastatin is the most widely prescribed statin in India and a cornerstone of cardiovascular risk reduction. This guide covers its pharmacology, Indian dosing practices, drug interactions, and safety monitoring.
Clinical Pharmacology Overview
Atorvastatin is an HMG-CoA reductase inhibitor (statin) that competitively inhibits the rate-limiting enzyme of cholesterol biosynthesis in the liver. This upregulates hepatic LDL receptors, increasing LDL-cholesterol clearance from the blood. It also reduces triglycerides and modestly raises HDL-cholesterol. Beyond lipid lowering, statins have pleiotropic effects including endothelial function improvement, anti-inflammatory properties, and plaque stabilisation.
Pharmacokinetics: Oral bioavailability is approximately 14% due to first-pass metabolism. Highly protein-bound (over 98%). Metabolised by CYP3A4 to active metabolites. Half-life of parent compound is 14 hours; active metabolites extend effective half-life to 20-30 hours. Primarily eliminated via bile.
Indian Brand Names
- Atorva (Zydus Cadila)
- Lipitor (Pfizer)
- Storvas (Sun Pharma)
- Atorlip (Cipla)
- Tonact (Lupin)
Approved Indications in Indian Clinical Practice
- Primary hypercholesterolaemia and mixed dyslipidaemia
- Secondary prevention of cardiovascular events in established atherosclerotic CVD
- Primary prevention of CV events in high-risk patients (diabetes, hypertension with additional risk factors)
- Acute coronary syndrome (high-intensity statin initiated early)
- Familial hypercholesterolaemia
Dosing in Adults
Low intensity: 10 mg once daily (reduces LDL by approximately 30%).
Moderate intensity: 10-20 mg once daily (reduces LDL by 30-50%). This is the most commonly used range in Indian practice.
High intensity: 40-80 mg once daily (reduces LDL by more than 50%). Reserved for ACS, established ASCVD, and familial hypercholesterolaemia.
Atorvastatin can be taken at any time of day (long half-life). Indian guidelines (ICMR, Cardiological Society of India) generally recommend starting at 10-20 mg and titrating based on lipid response.
Important Drug Interactions
- CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, HIV protease inhibitors, grapefruit juice): increase atorvastatin levels, raising myopathy risk
- Gemfibrozil: significantly increases statin myopathy risk (fenofibrate is preferred if combination needed)
- Cyclosporine: markedly increases atorvastatin levels -- use lowest dose
- Warfarin: may enhance anticoagulant effect; monitor INR
- Digoxin: atorvastatin may raise digoxin levels modestly
- Rifampicin: CYP3A4 inducer, reduces atorvastatin efficacy
Side Effects and Monitoring
Common: headache, myalgia, GI discomfort, elevated transaminases.
Serious: myopathy (CK more than 10x ULN with symptoms), rhabdomyolysis (rare but potentially fatal), hepatotoxicity (rare), new-onset diabetes mellitus (dose-related, class effect).
Monitoring: baseline lipid profile, liver transaminases, CK (if symptomatic). Repeat lipid profile at 6-8 weeks to assess response. Annual LFTs. CK only if muscle symptoms develop.
Special Populations
Pregnancy: Category X. Absolutely contraindicated. Statins must be discontinued before conception and throughout pregnancy and lactation. Cholesterol is essential for foetal development.
Renal impairment: No dose adjustment needed as elimination is primarily hepatic/biliary.
Hepatic impairment: Contraindicated in active liver disease or unexplained persistent transaminase elevation above 3x ULN.
Elderly: No dose adjustment but start low. Higher myopathy risk due to reduced muscle mass and polypharmacy.
NEET PG High-Yield Points
- HMG-CoA reductase is the rate-limiting enzyme of cholesterol synthesis
- Atorvastatin and rosuvastatin are the most potent statins
- Long half-life -- can be taken at any time (unlike simvastatin)
- Metabolised by CYP3A4 (rosuvastatin uses CYP2C9 -- fewer interactions)
- Myopathy risk increases with CYP3A4 inhibitors and gemfibrozil
- Category X in pregnancy -- absolute contraindication
- Pleiotropic effects: anti-inflammatory, endothelial protection, plaque stabilisation
- Statin intensity classification (low, moderate, high) is a common exam topic
- New-onset diabetes is a class effect, dose-dependent
Indian Regulatory Status
Atorvastatin is a Schedule H drug under the Drugs and Cosmetics Act. It is included in the NLEM of India and its price is regulated under DPCO (Drug Price Control Order). Fixed-dose combinations with ezetimibe, aspirin, or amlodipine are commonly available and are Schedule H. Generic atorvastatin is widely available and affordable in India.
Frequently Asked Questions
What is the usual dose of atorvastatin in Indian practice?
The starting dose is typically 10-20 mg once daily. Indian patients often respond to lower doses than Western populations. High-intensity therapy (40-80 mg) is used for acute coronary syndromes and established atherosclerotic CVD. The dose is taken at any time of day as atorvastatin has a long half-life.
When should statins be taken -- morning or night?
Atorvastatin can be taken at any time of day because it has a long half-life (14 hours for parent drug, 20-30 hours for active metabolites). This is unlike simvastatin, which should be taken at night due to its short half-life.
What are the muscle-related side effects of atorvastatin?
These range from myalgia (muscle pain without CK elevation, 5-10% of patients), to myopathy (muscle pain with CK elevation above 10x ULN), to rhabdomyolysis (rare, potentially fatal with renal failure). Risk increases with higher doses and interacting drugs.
Does atorvastatin interact with grapefruit?
Yes. Grapefruit inhibits intestinal CYP3A4 and can increase atorvastatin levels. Patients should avoid large quantities of grapefruit juice, though occasional small amounts are unlikely to cause clinically significant effects.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides